Back to Browse Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 6

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin

Authors Russo E, Penno G, Del Prato S

Published Date April 2013 Volume 2013:6 Pages 161—170

DOI http://dx.doi.org/10.2147/DMSO.S28951

Received 31 December 2012, Accepted 6 March 2013, Published 24 April 2013

Eleonora Russo, Giuseppe Penno, Stefano Del Prato

Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Disease, Azienda Ospedaliero Universitaria di Pisa, and University of Pisa, Pisa, Italy

Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel classified oral anti-diabetic drugs for the treatment of type 2 diabetes mellitus (T2DM) that provide important reduction in glycated hemoglobin, with a low risk for hypoglycemia and no weight gain. In T2DM patients with reduced renal function, adequate glycemic control is essential to delay the progress of kidney dysfunction, but they are at a greater risk of experiencing hypoglycemic events, especially with longer-acting sulfonylureas and meglitinides.
Objective: To evaluate vildagliptin as an option to achieve glycemic control in T2DM patients with moderate or severe chronic kidney disease (CKD).
Methods: A comprehensive search in the literature was performed using the term "vildagliptin." Original articles and reviews exploring our topic were carefully selected.
Results: Vildagliptin provides effective glycemic control in patients with T2DM and CKD. Dose reductions are required for vildagliptin and other DPP-4 inhibitors, except linagliptin, in T2DM patients with moderate-to-severe CKD. Dose of vildagliptin had to be reduced by half (to 50 mg/day) both for moderate (estimated glomerular filtration rate [eGFR] ≥30 to ≤50 mL/min) and severe CKD (eGFR < 30 mL/min). Available results support a favorable efficacy, safety, and tolerability profile for vildagliptin in T2DM with moderate or severe renal failure. Preliminary data may suggest additional benefits beyond improvement of glycemic control.
Conclusion: Vildagliptin can be safely used in T2DM patients with varying degrees of renal impairment. Dose adjustments for renal impairment are required. Potential long-term renal benefit of vildagliptin needs to be further explored.

Keywords: type 2 diabetes mellitus, renal function, chronic kidney disease

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Lorcaserin for weight management

Taylor JR, Dietrich E, Powell J

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:209-216

Published Date: 13 June 2013

Management of limited joint mobility in diabetic patients

Abate M, Schiavone C, Salini V, Andia I

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:197-207

Published Date: 7 May 2013

Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey

Sadosky A, Schaefer C, Mann R, Bergstrom F, Baik R, Parsons B, Nalamachu S, Nieshoff E, Stacey BR, Anschel A, Tuchman M

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:79-92

Published Date: 8 February 2013

Prevalence of overweight and obesity in adult Nigerians – a systematic review

Chukwuonye II, Chuku A, John C, Ohagwu KA, Imoh ME, Isa SE, Ogah OS, Oviasu E

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:43-47

Published Date: 22 January 2013